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Abstract
Background: Cost-effectiveness studies inform resource allocation, strategy, and policy development. However, due to their
complexity, dependence on assumptions made, and inherent uncertainty, synthesising, and generalising the results can be
difficult. We assess cost-effectiveness models evaluating expected health gains and costs of HIV pre-exposure prophylaxis
(PrEP) interventions.
Methods and Findings: We conducted a systematic review comparing epidemiological and economic assumptions of cost-
effectiveness studies using various modelling approaches. The following databases were searched (until January 2013):
PubMed/Medline, ISI Web of Knowledge, Centre for Reviews and Dissemination databases, EconLIT, and region-specific
databases. We included modelling studies reporting both cost and expected impact of a PrEP roll-out. We explored five
issues: prioritisation strategies, adherence, behaviour change, toxicity, and resistance. Of 961 studies retrieved, 13 were
included. Studies modelled populations (heterosexual couples, men who have sex with men, people who inject drugs) in
generalised and concentrated epidemics from Southern Africa (including South Africa), Ukraine, USA, and Peru. PrEP was
found to have the potential to be a cost-effective addition to HIV prevention programmes in specific settings. The extent of
the impact of PrEP depended upon assumptions made concerning cost, epidemic context, programme coverage,
prioritisation strategies, and individual-level adherence. Delivery of PrEP to key populations at highest risk of HIV exposure
appears the most cost-effective strategy. Limitations of this review include the partial geographical coverage, our inability to
perform a meta-analysis, and the paucity of information available exploring trade-offs between early treatment and PrEP.
Conclusions: Our review identifies the main considerations to address in assessing cost-effectiveness analyses of a PrEP
intervention—cost, epidemic context, individual adherence level, PrEP programme coverage, and prioritisation strategy.
Cost-effectiveness studies indicating where resources can be applied for greatest impact are essential to guide resource
allocation decisions; however, the results of such analyses must be considered within the context of the underlying
assumptions made.
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Introduction
Since the announcement of the results of HIV pre-exposure
prophylaxis (PrEP) trials and the HPTN052 early treatment for
prevention trial, there have been crucial policy discussions about
the use of antiretroviral (ARV) drugs to prevent HIV acquisition
or transmission. With regards to PrEP, encouraging results were
first reported for men and transgender women who have sex with
men in the iPrEX trial [1], which showed a 44% (95% CI 15–63)
reduction in HIV acquisition with a daily dose of tenofovir/
emtricitabine (TDF/FTC). In two large trials, the Partners PrEP
[2] and TDF2 [3] studies, PrEP was found to be effective in
reducing the risk of heterosexual HIV transmission using either
TDF or TDF/FTC daily (Partners PrEP) and TDF/FTC daily
(TDF2). However, FEM-PrEP [4], a trial recruiting heterosexual
women in South Africa, Tanzania, and Kenya for daily TDF/
FTC was closed prematurely in 2011 for futility as was the oral
TDF arm of the VOICE trial [5] in women in South Africa,
Uganda, and Zimbabwe. Two topical PrEP trials have tested the
efficacy of 1% TDF gel and a third, FACTS001 [6], is currently
recruiting women in South Africa. The CAPRISA 004 trial [7] in
Kwa Zulu-Natal found that pre- and post-coital vaginal TDF gel
reduced women’s acquisition risk by 39% (95% CI 6–60) but the
VOICE trial stopped its gel arm when it became evident that daily
gel use was safe but not effective [8].
Clinical guidance on oral PrEP has already been offered by the
US Centers for Disease Control and Prevention, the Southern
African HIV Clinicians Society, World Health Organization
(WHO), and the British Association for Sexual Health and HIV
[9–13]. An advisory panel to the US Food and Drug Adminis-
tration recently recommended oral TDF/FTC for preventive use
among people at higher risk of HIV exposure [14]. As PrEP
emerges as an option for inclusion in the HIV prevention toolbox,
it is important for national policy and decision makers to identify
where PrEP may fit best within already established HIV
prevention programming (and budgets) and the potential impli-
cations of introducing such policy changes. In particular, decision
makers need information translating the trial results into potential
population-level impact and cost-effectiveness to ensure that any
additional investment will have the maximum possible effect on
the epidemic.
Economic and mathematical models provide a framework to
integrate information on efficacy, effectiveness, costs, and patient
outcomes to support decision making and resource allocation [15].
However, due to their complexity, dependence on assumptions
made, and inherent uncertainties, generalising results from these
models can be difficult. In this review, we aim to assess published
cost-effectiveness models that have evaluated the expected health
gains and costs of PrEP interventions. Specifically, our objectives
are: (1) to describe modelling approaches of cost-effectiveness
analyses of PrEP; (2) to compare the effects of epidemiological and
cost assumptions on cost-effectiveness results; and (3) to explore the
potential impact on cost-effectiveness estimates of five issues raised
by policy makers [16–18] when considering PrEP implementation:
prioritisation, adherence, behaviour change, toxicity, and resistance.
Methods
We performed a systematic review of the published literature
following the protocol available in Text S2 and adhering to the
PRISMA guidelines for reporting of systematic reviews (Text S1:
PRISMA checklist) [19] and guidelines for appraisal of economic
evaluations [20].
Search Strategy, Inclusion Criteria, and Study Selection
A broad strategy using both MeSH headings and free text, with
no language limitations, was used to search PubMed/Medline, ISI
Web of Knowledge (including Web of Science, Current Contents
Connect, Derwent Innovations Index, CABI: CAB Abstracts, and
Journal Citation Reports), Centre for Reviews and Dissemination
databases (including DARE - Database of Abstracts of Reviews of
Effects, NHS EED - NHS Economic Evaluation Database, and
HTA database - health technology assessments), EconLIT, and
region-specific databases (African Index Medicus, Eastern Med-
iterranean Literature (WHO), Index Medicus for South-East Asia
Region, LILACS for Latin America). Our searches covered all
published research up to the last search performed 14 January
2013 with no limitations on publication date. The following
keywords were used: ‘‘cost’’ AND ‘‘tenofovir OR pre-exposure
prophylaxis OR chemoprophylaxis OR PrEP’’ AND ‘‘HIV.’’
Citations and bibliographies of full text reports retrieved were
reviewed for additional relevant articles. Abstracts from interna-
tional conferences identified in the searches were also reviewed, as
was the website of the International AIDS Economic Network.
Experts were consulted for additional studies. We included all
modelling studies reporting both cost and impact of a potential
roll-out of a PrEP programme. We excluded those studies where
costs were not assessed. No restrictions were made on the type of
model, geography, mode of transmission, or impact (effectiveness)
metric chosen. We included studies looking at both topical and
systemic PrEP products. Full published papers were eligible, as
well as abstracts from conferences providing sufficient information.
Two authors (GBG and AB) screened titles and abstracts to
identify potentially relevant articles. Full text reports of these
articles were assessed independently for inclusion.
Data Extraction and Analysis
Data were extracted from selected studies by one reviewer
(GBG) into prepared data sheets and independently cross-checked
by a second assessor (AB). For conference abstracts selected for
inclusion, we contacted the first author listed for further
information. Extracted information on the study design included
the type of study, viewpoint of analysis, timeframe, setting and
population, background HIV prevalence or incidence, mode of
HIV transmission, and a detailed description of alternative
programmes compared in the studies (baseline scenario and PrEP
scenario). We also tabulated data on the impact including risk
heterogeneity, efficacy or effectiveness of PrEP, adherence (to
programme or individual), behavioural change expected after
introduction of PrEP, resistance, toxicity due to PrEP use, and
disability-adjusted life year (DALY)/quality-adjusted life year
(QALY) assumptions. A description of economic assumptions
includes expected drug cost, other service costs, costs above service
level, downstream antiretroviral treatment (ART) costs averted,
discount rates, and, finally, cost-effectiveness results by metric and
the conclusions presented in each publication. Prioritised scenarios
were defined as those scenarios where PrEP was offered to specific
sub-populations within the population modelled. While providing
a critical assessment and narrative review of the studies included,
we did not attempt to perform a meta-analysis due to the
variability across the studies in reporting outcomes. Therefore, we
adjusted estimates of cost-effectiveness for inflation to US$2012 to
be able to compare studies from different years [21]. For those
studies reporting cost/DALY averted, cost/QALY averted, or
cost/life-year saved (LYS), we compared the estimates to a
benchmark for cost-effectiveness [22] of one times the gross
domestic product per capita (GDP/capita) per DALY averted, per
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QALY gained, or per LYS, depending on the unit of outcome
used by each study. While DALYs, QALYs, and LYS are not
equivalent, and decision rules vary by setting, this gives a broad
indication of potential cost-effectiveness. The values for current
GDP/capita were sourced from the World Bank databank for
each country [23]. There is much controversy around decision
rules [24], and while the comparison against GDP is the
conventional approach, it should be noted that this may not
represent the true opportunity cost in countries where less cost-
effective health interventions are not being implemented at scale.
Results
We screened 961 titles and abstracts retrieved from 14
electronic databases. After performing web searches and consult-
ing experts in the field, 36 full text articles were evaluated. We also
reviewed the reference lists and citations of these articles. Of these
36, 13 studies were included in the review [25–37]: 11 peer-
reviewed publications and two peer-reviewed conference abstracts
(Figure 1). Articles excluded are listed in Table S1 and a summary
of conclusions of the articles included are presented in Table S2.
We present in Tables 1 to 4 the data extracted from the studies
reviewed by study design, description of alternative programmes
compared, impact, and cost assumptions. All studies were
published between 2007 and 2013 and modelled the impact and
cost, from a health care provider perspective, of PrEP scale-up in
diverse settings. These settings included: heterosexual transmission
in generalised epidemics in sub-Saharan Africa—the Southern
Africa region [25], South Africa [28,30,31,32,36,37]), and other
modes of transmission in concentrated epidemics—among people
who inject drugs (PWID) in Ukraine [33]; and men who have sex
with men (MSM) in the USA [26,29,34,35] and in Peru [27].
Timeframes varied from 5 to 20 y. All studies focused the models
on high prevalence/incidence populations (Table 1).
In all models, the comparison scenario did not include PrEP
and assumptions varied regarding current treatment scale-up:
from no ART programme included [25,26,32] to ART coverage
remaining stable at a current level [27,29,31,34,35] or an ongoing
ART programme coverage expansion [28,30,33,36,37]. While
most of the studies looked at systemic PrEP (daily oral dosing), two
studies in South Africa looked at vaginal gels [31,32]. Coverage
assumptions were stated as scenarios. The criteria used to
characterise priority populations varied among the studies,
including high risk of acquisition (defined by sexual activity,
condom use, or HIV incidence) [25–27,35,37], age
[25,30,31,34,36], and timing of PrEP use [28] in relation to users’
life events (Table 2).
All models were transmission models, except for two Markov
simulations [31,34]. Efficacy and effectiveness estimates varied
from estimated ranges that were assumed prior to the results from
clinical trials and had wide ranges (from 10% to 90%)
[25,26,30,33,34] to estimates available directly from clinical trials
[27–29,31,32,35–37]. Several authors interpreted effectiveness as
being dependent on the product efficacy and the individual-level
Figure 1. Flow diagram of study selection. Region-specific databases can be accessed as follows: African Index Medicus, http://indexmedicus.
afro.who.int/; Eastern Mediterranean Literature, http://www.emro.who.int/; Index Medicus for South-East Asia Region, http://www.hellis.org/; LILACS,
Latin America, http://www.bireme.br/iah2/homepagei.htm.
doi:10.1371/journal.pmed.1001401.g001
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adherence, specifically modelling this interaction [25–29,32,36].
Adherence assumptions varied from random [25] to profiles based
on observations from published trials [27–29,32]. Potential
behaviour change following the introduction of a PrEP pro-
gramme was included in the models as an increase in the number
of sexual partners [25,26], changes in condom use [27,30], or both
[35]. Drug resistance associated with PrEP use was explicitly
modelled in one study [25], while in two further studies it was
Table 1. Study design.
Reference Study Type Setting/MoT Population Timeframe
HIV Incidence/
Prevalence
Generalised epidemics in southern Africa
Abbas [25] Deterministic simulation; Risk
heterogeneity by age, sex, sexual
behaviour, and HIV drug resistance
Southern Africa/
Heterosexual
15–49 y; General
population
10 y Prevalence: 20%a
Pretorius [30] Deterministic simulation; Risk
heterogeneity by age and sex
South Africa/
Heterosexual
15–49 y; General
population
10 y (programme
scale-up: 5 y)
Prevalence: 620% in
2008b
Hallett [28] Microsimulation; Risk heterogeneity
by age, sex, sexual behaviour, and
conception intentions or pregnancyc
South Africa/
Heterosexual
Serodiscordant
couples
Each person is tracked
until his/her 50th y
n/a
Williams [32] Deterministic simulation; Risk
heterogeneity not included
South Africa/
Heterosexual
15–49 y; General
population
From 2012 to 2020
(scale-up by 2015)
Prevalence:
approximately 16% in
2012b
Walensky [31] Monte Carlo state simulation; Risk
heterogeneity by age
South Africa/
Heterosexual
Women at higher
risk
Each person is
tracked until death
Incidence: ,25 y, 2.2%;
.25 y, 1.0%
Alistar [37] Compartmental dynamic simulation
Risk heterogeneity by sexual behaviour
behaviour (number of partners and
condom use)
South Africa/
Heterosexual
15–49 y; General
population
20 y Initial prevalence in
adults: 17.9% and initial
incidence: 1.4%
Cremin [36] Deterministic simulation;
Risk heterogeneity by age, sex, male
circumcision status, behavioural; risk
(partner change rate, condom use)
South Africa/
Heterosexual
15–54 y; General
population
10 y (programme
scale-up: 5 y)
Age- and sex-specific
prevalence peaking at
30–44 y (women: .40%
and 35–44 y men:
.30%).
Concentrated epidemics among MSM in high-income countries
Desai [26] Stochastic simulation; Risk heterogeneity
by age, sexual risk behaviourd
USA (NYC)/MSM 13–40 y; High
risk MSM
5 y Prevalence: 14.6% in
2008
Paltiel [34] Monte Carlo state simulation; Risk
heterogeneity by age (assumed higher
incidence by age group)
USA/MSM Average 34 y; High
risk MSM
Each person is
tracked until death
Incidence: 1.6% annual
Koppenhaver [29] Compartmental dynamic simulation
Risk heterogeneity not included
USA (urban)/MSM 13–40 y; All MSM 20 y Prevalence: 17.5%
Juusola [35] Deterministic simulation; Risk
heterogeneity by sexual behavioure
USA/MSM 13–64 y; 20 y Prevalence: 12.3%;
Incidence: 0.8% annual
Concentrated epidemics among MSM in low- and middle-income countries
Gomez [27] Deterministic simulation; Risk
heterogeneity by sexual behaviour
Peru (Lima)/MSM All MSM 10 y (programme
scale-up: 5 y)
Incidence: MMSM, 1%;
MMSW, 2.5%; SW, 3.1%;
Trans, 7.3%
Concentrated epidemics among PWID in low- and middle-income countries
Alistar [33] Compartmental dynamic simulation
Risk heterogeneity by IDU behaviour
Ukraine/IDU and
heterosexual
15–49 y 20 y Initial prevalence: 41.2%
PWID, 1% general
population
Study type refers to the type of model and the inclusion of risk heterogeneity in the population modelled. Setting/MoT refers to the geographical setting and the mode
of transmission modelled.
aFemale:male ratio 1.66, based on data from urban antenatal care attendees in Zambia.
bModel initiated at a high prevalence then fitted to Department of Health data.
cTwo types of couples were defined: (1) lower risk couples based on reported data from the Partners in Prevention HSV/HIV Transmission Study [49], and (2) couples at a
higher risk reflecting a higher incidence. ‘‘Partners in Prevention’’ assumptions: incidence low (1.8/100 person-years at risk, high condom use); ‘‘more typical couples’’
assumptions: 50% of serodiscordant couples involved HIV-1 infected men. Compared to the partners in prevention cohort: condom use within the stable partnership
was reduced by 25%, 50% more of the HIV-1 uninfected partners in couples had external partners, and frequency of unprotected sex with external partners was
doubled.
dVery high risk was defined as a participant reporting unprotected sex in the last 6 mo or in exchange for money or drugs, anonymous sex, $5 sexual or needle sharing
partners, and/or an STI diagnosis in the last 6 mo.
eThe authors run the model separately for low risk and high risk populations. Therefore PrEP use in one group does not have an impact on the other (the mixing is
considered totally assortative).
IDU, injection drug use; MMSM, men who mostly have sex with men; MMSW, men who mostly have sex with women; n/a, not applicable; SW, sex worker;
Trans, transgender or trans-sexual; USA (NYC), United States of America (New York City).
doi:10.1371/journal.pmed.1001401.t001
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Table 2. Alternative programmes compared.
Reference Base Comparison Scenario PrEP Intervention
PrEP
Regimen Prioritisation Coverage
Generalised epidemics in southern Africa
Abbas [25] No PrEP. ART was not modelled. Once daily
oral dosing
No prioritisation: general
population. By sexual activity: two
highest sexual activity groups
prioritised. By age: 15–20 y group
prioritised.
Percent of the population using PrEP:
Optimistic scenario, 75%; Neutral scenario,
50%; Pessimistic scenario, 25%
Pretorius [30] No PrEP. ART coverage expands at
its current rate. ART efficacy: 90%
reduction in transmission
probability.
Once daily
oral dosing
No prioritisation: 15–35 y; By age:
15–25 y, or 25–35 y
Percent of women using PrEP: 20%,
dropout rate:1.5%
Hallett [28] No PrEP. ART initiation for the infected
partner when CD4 cell count fell below
200 cells/ml. In a separate scenario,
expansion of eligibility criteria for ART
initiation was included (below 350 CD4
cells/ml).
Once daily
oral dosing
No prioritisation: Always use PrEP
after diagnosis partner. By timing:
Up to partner’s ART init; up to
partner’s ART init+1 y; during
conception/pregnancya
Percent of the population using PrEP:
see prioritisation
Williams [32] No PrEP. The scale-up of ARV
therapy was not modelled.
Vaginal gel,
two doses
pericoitally
PrEP used only by women Percent of sex acts protected: High:
90%, Medium: 50%, Low: 25%
Walensky [31] No PrEP. Patients identified as
HIV infected received ART as
per guidelines.
Vaginal gel,
two doses
pericoitally
PrEP used only by women. By
age: #25 y (high inc. group)
Cohort-wide PrEP use continues until
HIV infection or death.
Alistar [37] No PrEP. 40% HIV infected patients
received ART as per guidelines. ART
efficacy: 95% reduction in
transmission probability.
Once daily
oral dosing
No prioritisation: general use; By
sexual activity: groups of high
number of partners and low
condom use
Rate of recruitment into the program:
25%, 50%, 75%, 100%. Included a rate
of dropout from PrEP.
Cremin [36] ART efficacy: 96% reduction in transmission
probability. Baseline scenarios varied: from
status quo with current scale-up of ART to
counterfactual including MC and ART scale-up.
All scenarios included a 7/100 PY dropout rate
while on ART.
Once daily
oral dosing
No prioritisation: 15–54 y; By age:
15–24 y
Percent of the population group
using PrEP: 40%, 80%
Concentrated epidemics among MSM in high-income countries
Desai [26] No PrEP. The scale-up of ARV
therapy was not modelled.
Once daily
oral dosing
No prioritisation—results not
shown. Results for scenarios
targeting high risk MSM only.
25% high riskb; (5.2% of all MSM)c;
Discontinuation rate: 40% per year
Paltiel [34] No PrEP. Patients identified as HIV
infected received ART as per guidelines.
Once daily
oral dosing
No prioritisation: all MSM. By age:
,20 y.
Cohort-wide PrEP use continues
until HIV infection or death.
Koppenhaver
[29]
No PrEP. 25% of susceptible
and undiagnosed MSM are tested
per year, if eligible they start
ART as per guidelines.
Once daily
oral dosing
No prioritisation: all MSM. 100%
Juusola [35] No PrEP. Patients identified as HIV
infected received ART as per guidelines.
Once daily
oral dosing
No prioritisation: all MSM; By
sexual activity: high risk MSM.
100%, 50%, 20% of all MSM
or those at high riskd
Concentrated epidemics among MSM in low- and middle-income countries
Gomez [27] No PrEP. Patients identified as HIV
infected received ART as per guidelines
(CD4,200 cells/ml) to achieve 40% coverage.
Once daily
oral dosing
No prioritisation: uniform coverage.
By sexual activity: some and high
prioritisation.
Low 5%; High 20%
Concentrated epidemics among PWID in low- and middle-income countries
Alistar [33] No PrEP. Limited coverage of MMT and ART. Once daily
oral dosing
No prioritisation: all PWID: in
all cases, MMT and PrEP are
given only to PWID.
25%, 50% uninfected PWID. Included a
rate of dropout from PrEP.
aPeriod trying to conceive and while pregnant.
bThe authors also considered a scenario of 2.5% coverage, but explored results for the 25% scenario.
cDefined as those with more than five partners per y.
dCoverage includes only people fully adherent to PrEP.
init, initiation; MC, male circumcision; MMT, methadone maintenance treatment; n/a, not applicable.
doi:10.1371/journal.pmed.1001401.t002
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represented as a decrease in the rate of virologic suppression while
on subsequent treatment [31,34]. The studies did not assume any
reduction in the quality of life or disability weights due to PrEP
use, with the exception of three studies where toxicity to PrEP was
addressed through a reduction in the quality of life and/or an
excess fatality rate among PrEP users (Table 3) [31,34,35].
The majority of studies presented costs for PrEP programmes
including drugs and monitoring costs, except for two studies that
included drug costs only [25,32]. Costs above service level were
only included in two studies, as overheads [31] or a mark-up
percentage of 5% [27]. Overall PrEP programme costs were
consistent among studies by setting and ranged from high in the
USA (between US$8,000 and US$12,000 per person-year) to low
in South Africa (between US$80 to US$250). All cost estimates
were driven by the cost of drugs. Three studies in the USA
[26,29,35] and six in South Africa [28,30–32,36,37] included
averted ART costs. Ranges of estimated cost of ART were
consistent among studies and context-specific (,US$1,000 per
person-year in South Africa to .US$15,000 per person-year in
the USA) (Table 4).
We present all cost-effectiveness estimates in Table 5 by
epidemiological context and scenario modelled.
Generalised Epidemics in Southern Africa (n= 7)
Studies on topical PrEP and two studies on oral PrEP suggest
the intervention to be cost-effective (topical PrEP: ,200 US$/
DALY [32], ,3,000 US$/LYS [31]; oral PrEP: ,5,000 US$/
QALY [28],,2,800 US$/QALY [37]) using benchmarks for cost-
effectiveness specific to South Africa [22]. Three studies reported
cost/infection averted only, estimates ranging from US$1,000 to
39,900 [25,30,36].
For topical PrEP, the two studies presented different estimates of
cost-effectiveness: less cost-effective in Walensky et al. [31]
(,US$1,600–US$2,700/life year saved) than in Williams et al.
[32] (,US$18–US$181/DALY averted) due to a more compre-
hensive set of assumptions in the former (i.e., inclusion of the
above service level costs of providing PrEP, adverse outcomes,
topical PrEP toxicity, and resistance as well as a lifelong use of
PrEP and discounting) [31,32]. Prioritisation to high-risk key
populations (high incidence groups, such as young women in
South Africa) and improvements in adherence maximised the
effectiveness of a topical PrEP programme [31,32].
For oral PrEP, the impact was estimated to be higher if PrEP
was prioritised for use among people at higher risk of HIV
acquisition compared to no prioritisation strategy in four of the
five studies included (i.e., higher sexual activity groups in Abbas et
al. [25], couples at higher risk in Hallett et al. [28], people with
high number of partners and low condom use in Alistar et al. [37],
and younger women in Pretorius et al. [30]). In Cremin et al. [36],
the authors compared PrEP prioritised to 15 to 24 years old to no
prioritisation (PrEP available to the total adult population: 15 to
54 years old) and found the impact of the two strategies was very
similar. However, the group prioritised (15 to 24 years old) did not
present the highest risk of infection in this population. The impact
of prioritising by age may be more evident when the intervention
is aimed at age groups where incidence peaks (in this case among
the 25- to 34-year age group).
Four studies analysed the interactions between oral PrEP and an
expanding ART programme. Pretorius et al. found oral PrEP cost-
effectiveness and its impact at population level to be considerably
reduced if PrEP is added to the expanding ART programme [30].
Accordingly, Alistar et al. and Cremin et al. found that expanding
ART coverage in this setting will be the more attractive strategy
than investing in oral PrEP [36,37]. However, Alistar et al. found
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Table 5. Cost-effectiveness estimates by scenario.
Reference Scenario Description: Prioritisation Estimate
Measure
US$ in
Publication 2012US$
Generalised epidemics in southern Africa
Abbas [25] Pessimistic: high sexual activity group Cost/infection averted 2,949–9,923 3,450–11,609
Pessimistic: 15–20 y Cost/infection averted 20,202–67,970 23,636–79,525
Pessimistic: no prioritisation Cost/infection averted 20,164–67,842 23,591–79,375
Neutral: high sexual activity group Cost/infection averted 1,160–3,904 1,357–4,567
Neutral: 15–20 y Cost/infection averted 8,968–30,173 10,492–35,302
Neutral: no prioritisation Cost/infection averted 9,629–32,398 11,265–37,905
Optimistic: high sexual activity group Cost/infection averted 638–2,147 746–2,512
Optimistic: 15–20 y Cost/infection averted 5,723–19,254 6,695–22,527
Optimistic: no prioritisation Cost/infection averted 6,812–22,918 7,970–26,814
Pretorius [30] Optimistic: women 15–25 y, no behaviour change Cost/infection averted .25,000 .26,625
Optimistic: women 15–35 y, no behaviour change Cost/infection averted .22,500 .23,963
Optimistic: women 25–35 y, no behaviour change Cost/infection averted .20,000 .21,300
Medium efficacy: women 25–35 y, behaviour change Cost/infection averted .30,000 .31,950
Hallett [28] Efficacy range, high risk: conception or pregnancy use Cost/infection averted 26,000 to 8,000 26,192 to 8,256
Efficacy range, low risk: conception or pregnancy use Cost/infection averted 22,000 to 12,000 22,064 to 12,384
Efficacy range, high risk: up to ART initiation Cost/infection averted 22,200 to 21,000 22,270.4 to 21,672
Efficacy range, high risk: always use PrEP Cost/infection averted 0–26,000 0–26,832
Efficacy range, low risk: always use PrEP Cost/infection averted 6,000–66,000 6,192–68,112
Optimistic, low risk, high ART cost: up to ART initiation Cost/infection averted 3,000 3,096
Optimistic, low risk, high ART cost: up to ART initiation +1 y Cost/infection averted 3,000 3,096
Optimistic, high risk: up to ART initiation Cost/QALY gained 2200 to 500 2206a to 516a
Optimistic, low risk: up to ART initiation Cost/QALY gained 260–1,600 268a–1,651a
Pessimistic, high risk: up to ART initiation Cost/QALY gained 700–1,900 722a–1,960a
Pessimistic, low risk: up to ART initiation Cost/QALY gained 2,500–4,900 2,580a–5,056a
Williams [32] CAPRISA efficacy: high coverage Cost/infection averted 420–2,982 447–3,175
CAPRISA efficacy: low coverage Cost/infection averted 562–4,222 598–4,496
CAPRISA efficacy: high coverage Cost/DALY averted 18–130 19a–138a
CAPRISA efficacy: low coverage Cost/DALY averted 27–181 28a–193a
Walensky [31] CAPRISA efficacy, test freq 3 mo: high incidence women Cost/life year saved 1,600 1,704a
CAPRISA efficacy, test freq 1 mo: high incidence women Cost/life year saved 2,700 2,876a
Alistar [37]b PrEP: no prioritisation recruitment rate 25% to 100%, no ART expansion Cost/QALY gained 1,200 1,200a
PrEP: high risk group recruitment rate 50% to 100%, no ART expansion Cost/QALY gained CS CSa
PrEP: no prioritisation recruitment rate 25% to 100%, ART +25% as per guidelines Cost/QALY gained 980–1,050 980a–1,050a
PrEP: high risk group recruitment rate 100%, ART +25% as per guidelines Cost/QALY gained 50 50a
PrEP: no prioritisation recruitment rate 25% to 100%, ART +50% as per guidelines Cost/QALY gained 900–1,000 900a–1,000a
PrEP: high risk group recruitment rate 100%, ART +50% as per guidelines Cost/QALY gained 160 160a
PrEP: no prioritisation recruitment rate 25% to 100%, ART +75% as per guidelines Cost/QALY gained 860–970 860a–970a
PrEP: high risk group recruitment rate 100%, ART +75% as per guidelines Cost/QALY gained 210 210a
PrEP: no prioritisation recruitment rate 25% to 100%, ART +100% as per guidelines Cost/QALY gained 840–950 840a–950a
PrEP: high risk group recruitment rate 100%, ART +100% as per guidelines Cost/QALY gained 230 230a
PrEP: no prioritisation recruitment rate 25% to 100%, universal ART +25% Cost/QALY gained 810–940 810a–940a
PrEP: high risk group recruitment rate 100%, universal ART +25% Cost/QALY gained 220 220a
PrEP: no prioritisation recruitment rate 25% to 100%, universal ART +50% Cost/QALY gained 760–900 760a–900a
PrEP: high risk group recruitment rate 100%, universal ART +50% Cost/QALY gained 280 280a
PrEP: no prioritisation recruitment rate 25% to 100%, universal ART +75% Cost/QALY gained 740–890 740a–890a
PrEP: high risk group recruitment rate 100%, universal ART +75% Cost/QALY gained 290 290a
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Table 5. Cont.
Reference Scenario Description: Prioritisation Estimate
Measure
US$ in
Publication 2012US$
PrEP: no prioritisation recruitment rate 25% to 100%, universal ART +100% Cost/QALY gained 740–880 740a–880a
PrEP: high risk group recruitment rate 100%, universal ART +100% Cost/QALY gained 300 300a
Cremin [36]c PrEP: no prioritisation, cov 4.4% of 15–54 y (baseline: status quo, current
ART scale-up)
Cost/infection averted 9,390 9,390
PrEP: prioritisation, cov 7.3% of 15–24 y (baseline: status quo, current
ART scale-up)
Cost/infection averted 10,540 10,540
No PrEP, 80% universal ART (baseline: 80% ART200 and 80% MC) Cost/infection averted 10,530 10,530
PrEP: 15–24 y cov 40%, 80% universal ART (baseline: 80% ART200, 80% MC,
80% ART350)
Cost/infection averted 39,900 39,900
PrEP: 15–54 y cov 80%, 80% universal ART (baseline: 80% ART200, 80% MC) Cost/infection averted 20,500 20,500
Concentrated epidemics among MSM in high-income countries
Desai [26]d Exposure, pessimistic: high adherence Cost/QALY gained 6,661–36,268 7,793e–42,433e
Exposure, pessimistic: medium adherence Cost/QALY gained 55,167–84,774 64,545f–99,185f
Exposure, pessimistic: low adherence Cost/QALY gained 113,601–143,208 132,913f–167,553
Adherence, pessimistic: high adherence Cost/QALY gained CS–8,158 CSe–9,545e
Adherence, pessimistic: medium adherence Cost/QALY gained CS–10,327 CSe –12,082e
Adherence, pessimistic: low adherence Cost/QALY gained CS–13,499 CSe –15,793e
Basic, pessimistic: high adherence Cost/QALY gained CS–15,099 CSe –17,665e
Basic, pessimistic: medium adherence Cost/QALY gained 17,168–46,775 20,086e–54,726f
Basic, pessimistic: low adherence Cost/QALY gained 66,896–96,502 78,268f–112,907
Exposure, optimistic: high adherence Cost/QALY gained CS–9,925 CSe –11,612e
Exposure, optimistic: medium adherence Cost/QALY gained 13,307–42,914 15,569e–50,209f
Exposure, optimistic: low adherence Cost/QALY gained 46,502–76,109 54,407f–89,047f
Adherence, optimistic: high adherence Cost/QALY gained CS CSe
Adherence, optimistic: medium adherence Cost/QALY gained CS CSe
Adherence, optimistic: low adherence Cost/QALY gained CS CSe
Basic, optimistic: high adherence Cost/QALY gained CS–1,009 CSe –1,180e
Basic, optimistic: low adherence Cost/QALY gained 37,947–67,553 44,398e–79,037f
Basic, optimistic: medium adherence Cost/QALY gained CS–28,393 CSe –33,220e
Paltiel [34] Medium efficacy: no prioritisation Cost/QALY gained 298,000 359,984
High efficacy: no prioritisation Cost/QALY gained 107,000 129,256f
Medium efficacy, low cost Cost/QALY gained 114,000 137,712f
Medium efficacy: young Cost/QALY gained 189,000 228,312
Koppenhaver
[29]
High adherence: no prioritisation Cost/QALY gained 353,739 376,732
iPrEX adherence: no prioritisation Cost/QALY gained 570,273 607,341
Juusola [35] Cov 100%, PrEP cost US$26/d, no resistance: high risk MSM Cost/QALY gained 52,443 55,852f
Cov100%, PrEP cost US$26/d, no resistance: no prioritisation Cost/QALY gained 216,480 230,551
Cov 100%, high eff, PrEP cost US$26/d, no resistance: high risk MSM Cost/QALY gained 35,080 37,360e
Cov 100%, high eff, PrEP cost US$26/d, no resistance: no prioritisation Cost/QALY gained 146,228 155,733
Cov 100%, PrEP cost US$15/d, no resistance: no prioritisation Cost/QALY gained 131,277 139,810f
Cov 100%, PrEP cost US$50/d, no resistance: high risk MSM Cost/QALY gained 104,516 111,310f
Cov 100%, PrEP cost (50% ARV), no resistance: high risk MSM Cost/QALY gained 25,165 26,801e
Cov 100%, PrEP cost (75% ARV), no resistance: high risk MSM Cost/QALY gained 38,804 41,326e
Cov 100%, no resistance, 8% reduction QoL: high risk MSM. Cost/QALY gained 95,006 101,181f
Cov 100%, PrEP cost US$26/d, resistance: high risk MSM Cost/QALY gained 57,861 61,622f
Cov 100%, PrEP cost US$26/d, resistance: no prioritisation Cost/QALY gained 233,040 248,188
Cov 50%, PrEP cost US$26/d, no resistance: high risk MSM Cost/QALY gained 44,556 47,452e
Cov50%, PrEP cost US$26/d, no resistance: no prioritisation Cost/QALY gained 188,421 200,668
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PrEP to be cost saving, when delivered to individuals at greater
risk of infection with no ART expansion [37]. Cremin et al. [36]
found that a PrEP intervention was not cost-saving when
implemented on top of a base case that included an 80% coverage
of ART for people with CD4 counts of less than 200 cells/ml and
male circumcision to be scaled up to 80%. Hallett et al. compared
Table 5. Cont.
Reference Scenario Description: Prioritisation Estimate
Measure
US$ in
Publication 2012US$
Cov 50%, high eff, PrEP cost US$26/d, no resistance: high risk MSM Cost/QALY gained 26,766 28,506e
Cov 50%, high eff, PrEP cost US$26/d, no resistance: no prioritisation Cost/QALY gained 120,080 127,885f
Cov 50%, PrEP cost US$15/d, no resistance: no prioritisation Cost/QALY gained 113,935 121,341f
Cov 50%, PrEP cost US$50/d, no resistance: high risk MSM Cost/QALY gained 89,658 95,486f
Cov 50%, PrEP cost (50% ARV), no resistance: high risk MSM Cost/QALY gained 20,930 22,290e
Cov 50%, PrEP cost (75% ARV), no resistance: high risk MSM Cost/QALY gained 32,743 34,871e
Cov 50%, no resistance, 8% reduction QoL: high risk MSM. Cost/QALY gained 72,762 77,492f
Cov 50%, PrEP cost US$26/d, resistance: high risk MSM Cost/QALY gained 56,492 60,164f
Cov 50%, PrEP cost US$26/d, resistance: no prioritisation Cost/QALY gained 226,325 241,036
Cov 20%, PrEP cost US$26/d, no resistance: high risk MSM Cost/QALY gained 40,279 42,897e
Cov20%, PrEP cost US$26/d, no resistance: no prioritisation Cost/QALY gained 172,091 183,277
Cov 20%, high eff, PrEP cost US$26/d, no resistance: high risk MSM Cost/QALY gained 22,374 23,828e
Cov 20%, high eff, PrEP cost US$26/d, no resistance: no prioritisation Cost/QALY gained 105,066 111,895f
Cov 20%, PrEP cost US$15/day, no resistance: no prioritisation Cost/QALY gained 103,841 110,591f
Cov 20%, PrEP cost US$50/d, no resistance: high risk MSM Cost/QALY gained 81,593 86,897f
Cov 20%, PrEP cost (50% ARV), no resistance: high risk MSM Cost/QALY gained 18,637 19,848e
Cov 20%, PrEP cost (75% ARV), no resistance: high risk MSM Cost/QALY gained 29,458 31,373e
Cov 20%, no resistance, 8% reduction QoL: high risk MSM Cost/QALY gained 62,431 66,489f
Cov 20%, PrEP cost US$26/d, resistance: high risk MSM Cost/QALY gained 78,884 84,011f
Cov 20%, PrEP cost US$26/d, resistance: no prioritisation Cost/QALY gained 303,091 322,792
Concentrated epidemics among MSM in low- and middle-income countries
Gomez [27] Low coverage: high prioritisation Cost/DALY averted 403–637 415g–657g
Low coverage: some prioritisation Cost/DALY averted 447–707 461g–729g
Low coverage: no prioritisation Cost/DALY averted 1,076–1,702 1,110g–1,756g
High coverage: high prioritisation Cost/DALY averted 665–1,052 686g–1,085g
High coverage: some prioritisation Cost/DALY averted 886–1,400 914g–1,445g
High coverage: no prioritisation Cost/DALY averted 1,125–1,779 1,161g–1,835g
Concentrated epidemics among PWID in low- and middle-income countries
Alistar [33] MMT 25%, no PrEP Cost/QALY gained 530 546h
MMT 25%, ART 80% (for IDU and general population), no PrEP Cost/QALY gained 870 896h
MMT 25%, ART 80% (for IDU and general population), PrEP 25% to 50% Cost/QALY gained 3,080–3,910 3,172h–4,027i
PrEP 25% to 50% Cost/QALY gained 14,590–14,680 15,028–15,120
MMT 25%, PrEP 25% to 50% Cost/QALY gained 4,800–6,100 4,944i–6,283i
ART 80% (for IDU and general population), PrEP 25% to 50% Cost/QALY gained 3,290–4,210 3,389h–4,336i
Thresholds used to determine cost-effectiveness, based on World Bank database [23]. Bold-black signifies an estimate is cost-effective or very cost-effective with regards
to the country-specific threshold.
aFor South Africa, an intervention is considered very cost-effective at a threshold of less than 16GDP per capita, US$8,070.
bIn Alistar et al., several scenarios were considered for ART recruitment rates of 25%, 50%, 75%, and 100% in addition to the 40% status quo coverage as per guidelines
and following universal access.
cIn Cremin et al., several scenarios were considered for ART coverage. ART200: coverage of ART in HIV-infected people starting at CD4 count of ,200 cells/ml; ART350:
coverage of ART in HIV-infected people starting at CD4 count of ,350 cells/ml; universal ART: coverage of ART in HIV-infected people starting at any CD4 count level.
dIn Desai et al., the authors considered three effectiveness mechanisms: basic, adherence-dependent, and exposure-dependent.
eFor USA, an intervention is considered very cost-effective at a threshold of less than 16GDP per capita, US$48,442.
fFor USA, an intervention is considered cost-effective between 16GDP per capita, US$48,442 and 36GDP per capita, US$145,326.
gFor Peru, an intervention is considered very cost-effective at a threshold of less than 16GDP per capita, US$ US$6,009.
hFor Ukraine, an intervention is considered very cost-effective at a threshold of less than 16GDP per capita, US$3,615.
iFor Ukraine, an intervention is considered cost-effective between 16GDP per capita, US$3,615 and 36GDP per capita, US$10,845.
cov., coverage; CS, cost saving; freq, frequency; MC, male circumcision; MMT, methadone maintenance treatment; QoL, quality of life; resist., resistance.
doi:10.1371/journal.pmed.1001401.t005
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early ART to PrEP in HIV-serodiscordant couples, finding that if
higher risk couples change their behaviour (for example through
risk reduction counselling), earlier initiation of ART might become
a cost-effective alternative to oral PrEP [28]. Assumptions about
behavioural change (an increase in the number of partners) was a
key driver of cost-effectiveness in Abbas et al. [25], while Pretorius
et al. [30] found a lesser impact on cost-effectiveness following
changes in condom use. This might be explained by the inclusion
in Pretorius et al. of a background decrease in condom use with
age, with older women tending to have less condom use. Hallett et
al. did not include changes in behaviour due to oral PrEP
introduction in their analyses. Resistance and toxicity levels did
not significantly affect cost-effectiveness estimates [25,31].
Concentrated Epidemics among MSM in the USA (n=4)
Pre-iPrEX modelling studies estimated cost-effectiveness of
PrEP interventions among MSM with mixed results in the USA.
The cost per QALY gained presented by Paltiel et al. [34] was
considerably higher (US$298,000/QALY gained) than that
presented by Desai et al. [26] (from cost saving to a maximum
of US$143,208/QALY gained). This difference is primarily due to
the inclusion of benefits from reduced onward transmission in the
latter. The authors of post-iPrEX studies are in agreement that
PrEP use among populations of MSM in the USA could have a
significant impact on the domestic HIV epidemic. However,
Koppenhaver et al., while exploring only scenarios with no
prioritisation, found a PrEP intervention not to be cost-effective
[29]. Juusola et al. found PrEP to be cost-effective under certain
assumptions (i.e., prioritisation scenarios and no prioritisation
scenarios including high product effectiveness or low drug costs
[US$15/day for oral PrEP to the equivalent of 50% or 75% the
cost of ART]) [35]. Both studies concluded that a PrEP
programme might not be affordable due to the high cost of drugs
used for PrEP (US$8,000 to US$9,300 per person-years for PrEP
drugs only) [29,35]. In this setting, the benefits of PrEP were
expected to be offset by relatively small increases in the number of
partners in one study [26]. Conversely, resistance was not found to
have a strong impact on cost-effectiveness estimates [34,35].
Varying levels of toxicity to PrEP had the potential to
counterbalance PrEP benefits in two studies [34,35].
Concentrated Epidemics among MSM in Peru (n=1)
PrEP could be a cost-effective addition to current prevention
programmes in Peru for MSM populations (up to US$1,702/
DALY averted) using benchmarks for cost-effectiveness specific to
Peru [22]. However, even if PrEP drugs are expected to cost less
than in settings such as the USA, a PrEP programme in this
middle-income country might well require significant expenditure
[27]. Behaviour change was not estimated to significantly affect
cost-effectiveness estimates. It would result in detrimental effects
(increases in the number of infections) only if PrEP efficacy and
adherence were both assumed to be low [27]. The effect of
prioritisation appears to be less pronounced in those scenarios with
high coverage levels where saturation of coverage of those at
highest risk occurs early during implementation and higher levels
of coverage of lower-risk populations is achieved [27].
Concentrated Epidemics among People Who Inject
Drugs in Ukraine (n= 1)
Alistar et al. [33] found PrEP not to be a cost-effective
intervention in isolation from other HIV control interventions for
use among populations of PWID (US$14,590–US$14,680/QALY
gained) using benchmarks for cost-effectiveness specific to Ukraine
[22]. PrEP is considerably less attractive when compared to the
expansion of either methadone maintenance therapy (US$530/
QALY gained) or to the combination of methadone maintenance
therapy and ART for those in need (US$870/QALY gained) [33].
Discussion
This systematic review included 13 modelling studies estimating
the cost and potential population-level impact of introducing a
PrEP programme in generalised and concentrated epidemic
settings. Our findings show that PrEP is estimated to have the
potential to be a cost-effective addition to HIV prevention
programmes in some settings. However, the cost-effectiveness of
PrEP is likely to depend on considerations such as cost, the
epidemic context, PrEP programme coverage and prioritisation
strategies, as well as individual adherence levels and PrEP efficacy
estimates.
To prevent heterosexual transmission in the generalised
epidemics of southern Africa, PrEP is potentially a cost-effective
intervention. Topical PrEP, in particular, could have a significant
impact in South Africa, providing a much-needed female-initiated
prevention option. However, it should be noted that funding PrEP
while other potentially more cost-effective HIV prevention
interventions remain under-funded may have high opportunity
costs. In concentrated epidemics, such as MSM-driven epidemics
both in Peru and in the USA, PrEP could have a substantial
impact on the epidemic but may not be affordable at current drug
prices. In Ukraine, expansion of ART coverage and methadone
maintenance treatment programmes for PWID should be a first
priority, with PrEP potentially added on within a combination
prevention framework. However, evidence to date shows PrEP
might not be cost-effective in this setting at current drug prices.
Nevertheless, findings from the phase III Bangkok Tenofovir
Study of PrEP among PWID will shed light on the efficacy
estimates of PrEP in this population and inform future model
estimates in similar epidemic contexts [38].
In all settings, the price of drugs is a limiting factor in terms of
affordability of PrEP programmes as has been previously suggested
[39,40], and is key to determining cost-effectiveness. Moreover,
the findings above predominately exclude important service and
above service costs of providing PrEP (i.e., regular HIV testing and
blood chemistry panels; the costs of possible adverse outcomes,
including PrEP-related toxicity and potential drug resistance
attributable to PrEP; and system-wide costs of implementing a
PrEP programme). All of these should be considered to improve
the validity and utility of estimates. Another key limitation among
the studies is that the majority did not include savings in treatment
and hospitalisation due to secondary infections averted. Although
carrying significant uncertainties, the inclusion of these benefits
allows a more informed consideration of potential PrEP benefits
within broader programmatic planning for HIV prevention and
care.
In the models reviewed, several prioritisation strategies were
explored. Prioritisation by sexual activity characteristics to deliver
PrEP to those populations at highest risk of HIV exposure
improved the cost-effectiveness estimates. However, the extent to
which prioritising populations at higher risk improves cost-
effectiveness results in the models depends largely on the
assumptions made about sexual mixing and risk heterogeneity.
Extra costs related to the identification and engagement of priority
populations were not included in any of the studies, neither were
considerations in terms of economies of scale. Furthermore, as
results from the enrolment phase of iPrEX Ole show (65% of trial
participants decided to continue taking PrEP), not all individuals at
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higher risk are willing to use PrEP [41]. Identifying and
meaningfully engaging those at highest risk in tailored HIV
prevention strategies represents a significant challenge for decision
makers, health care providers, and prevention advocates.
Prioritisation by age was a strategy advanced in several studies.
In the studies reviewed, prioritisation by age group resulted in a
lower cost-effectiveness benefit compared to prioritisation strate-
gies based on self-reported risk behaviour [25,30,31,34]. However,
the former has the advantage of being straightforward to
implement compared to a selection of potential PrEP users based
on self-reported risk behaviour. In contexts such as South Africa
and the USA, age prioritisation clearly would focus on those
populations at higher risk of HIV acquisition. Another prioritisa-
tion strategy analysed in one study was the delivery of PrEP
depending on the stage in users’ lives. In reality, PrEP use will not
need to be sustained throughout an individual’s lifetime but may
vary as his or her risk situation changes over time. People may opt
to use PrEP during specific higher risk life periods, such as during
periods of active sex work or when serodiscordant couples are
trying to conceive a child [42,43]. Understanding potential
scenarios of PrEP use over the life cycle is essential for decision
makers to be able to evaluate the possible impact of PrEP
programmes in their local contexts. An additional consideration
concerns intermittent PrEP. The first report of safety and
adherence to an intermittent PrEP regimen in Kenya showed
that among MSM and female sex workers adherence was lower
than for daily dosing [44]. Results from two phase II trials
underway in France [45] and the USA [46] will help inform
adherence requirements and, should intermittent pre- and post-
exposure dosing be proven effective, help tailor PrEP programmes
to consumer demand [47].
Behavioural change due to PrEP use and adherence to PrEP
were estimated to have potentially significant impacts on
programme effectiveness. While the emergence of drug resistance
due to PrEP programme scale-up and PrEP-related toxicity
assumptions did not significantly affect cost-effectiveness estimates,
improvement of drug resistance surveillance systems as well as
effective adherence counselling will be essential components of
PrEP programme implementation, in addition to behavioural
counselling.
This review has several limitations. The geographical coverage
of the studies reviewed is partial and both the impact and cost
evaluations are highly setting-specific, limiting the generalisability
of the findings. We were unable to perform a meta-analysis due to
the variability across studies in reporting outcomes. Nevertheless,
in order to compare cost-effectiveness estimates across settings, we
used the thresholds proposed by the WHO-CHOICE Project and
the Commission on Macroeconomics as a benchmark [22]. These
standards are based on the GDP per capita, assuming that a
society is willing to pay the equivalent of up to one GDP per capita
(for highly cost-effective interventions) or between one and three
times the GDP per capita (for a cost-effective intervention for a
DALY averted, QALY saved, or LYS). This is a normative
selection of cost-effectiveness thresholds, albeit regarded as useful
from a decision analytic perspective [24].
It is worth noting that, with the exception of four studies in
South Africa [28,30,36,37], research comparing the potential
trade-offs of earlier treatment for prevention versus PrEP remains
an important gap in the literature that should be addressed,
especially in concentrated epidemics. Cost-effectiveness studies
that demonstrate where resources applied can have the greatest
impact will help inform this complicated decision-making, but
these are not the only considerations. The decision to include a
PrEP option within the combination prevention package requires
input from all strata of society. For instance, in contexts where
universal access to ART for patients in need has not been
achieved, PrEP programme planning processes will be challenged
by concerns about social justice, equity, and affordability. This is
in addition to the hurdles of overcoming the marginalisation,
stigmatisation, and criminalisation of many of the populations that
would most benefit from tailored HIV prevention programming
that includes the choice of PrEP. Disentangling these issues will be
critical for effective decision-making, as will the consideration of
potential synergies between an expanded testing and treatment
programme and a PrEP programme.
While the interest of donors for modelling studies that compare
the cost-effectiveness of different HIV prevention methods is
expected to increase [48], current evidence is already available to
aid policy makers in assessing PrEP as a new prevention option. In
this context, our review sheds light on the main considerations that
decision makers need to address when judging the relevance of
cost-effectiveness estimates of a potential PrEP programme and
the potential gaps in the modelling evidence. Given that our
review shows that setting and target population are critical drivers
of cost-effectiveness, the next step is to conduct context-specific
demonstration studies, including comprehensive cost analyses, of
different prioritisation and adherence promotion strategies to
ensure that the maximum benefit from the introduction of PrEP is
realised within combination HIV prevention programmes.
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Editors’ Summary
Background Every year approximately 2.5 million people
are infected with HIV, the virus that causes AIDS. Behavioral
strategies like condom use and reduction of sexual partners
have been the hallmarks of HIV prevention efforts. However,
biological prevention measures have also recently been
shown to be effective. These include male circumcision,
treatment as prevention (treating HIV-infected people with
antiretroviral drugs to reduce transmission), and pre-expo-
sure prophylaxis (PrEP), where people not infected with HIV
take antiretroviral drugs to reduce the probability of
transmission. Strategies such as PrEP may be viable
prevention measure for couples in long-term relationships
where one partner is HIV-positive and the other is HIV-
negative (HIV serodiscordant couples) or groups at higher
risk of HIV infection, such as men who have sex with men,
and injection drug users.
Why Was This Study Done? The findings from recent
clinical trials that demonstrate PrEP can reduce HIV trans-
mission have led to important policy discussions and in the
US, Southern Africa, and the UK new clinical guidelines have
been developed on the use of PrEP for the prevention of HIV
infection. For those countries that are considering whether
to introduce PrEP into HIV prevention programs, national
policy and decision makers need to determine potential
costs and health outcomes. Cost-effectiveness models—
mathematical models that simulate cost and health effects of
different interventions—can help inform such decisions.
However, the cost-effectiveness estimates that could provide
guidance for PrEP programs are dependent on, and limited
by, the assumptions included in the models, which can make
their findings difficult to generalize. A systematic comparison
of published cost-effectiveness models of HIV PrEP interven-
tions would be useful for policy makers who are considering
introducing PrEP intervention programs.
What Did the Researchers Do and Find? The researchers
performed a systematic review to identify published cost-
effectiveness models that evaluated the health gains and
costs of HIV PrEP interventions. Systematic reviews attempt
to identify, appraise, and synthesize all the empirical
evidence that meets pre-specified eligibility criteria to
answer a given research question by using explicit methods
aimed at minimizing bias. By searching databases the
authors identified 13 published studies that evaluated the
impact of PrEP in different populations (heterosexual
couples, men who have sex with men, and injection drug
users) in different geographic settings, which included
Southern Africa, Ukraine, US, and Peru.
The authors identified seven studies that assessed the
introduction of PrEP into generalized HIV epidemics in
Southern Africa. These studies suggest that PrEP may be a
cost effective intervention to prevent heterosexual transmis-
sion. However, the authors note that funding PrEP while
other cost-effective HIV prevention methods are underfund-
ed in this setting may have high opportunity costs. The
authors identified five studies where PrEP was introduced for
concentrated epidemics among men who have sex with men
(four studies in the US and one in Peru). These studies
suggest that PrEP may have a substantial impact on the HIV
epidemic but may not be affordable at current drug prices.
The authors also identified a single study that modeled the
introduction of PrEP for people who inject drugs in the
Ukraine, which found PrEP not to be cost effective.
In all settings the price of antiretroviral drugs was found to
be a limiting factor in terms of affordability of PrEP programs.
Behavioral changes and adherence to PrEP were estimated
to have potentially significant impacts on program effec-
tiveness but the emergence of drug resistance or PrEP-
related toxicity did not significantly affect cost-effectiveness
estimates. Several PrEP prioritization strategies were ex-
plored in included studies and delivering PrEP to populations
at highest risk of HIV exposure was shown to improve cost-
effectiveness estimates. However, the extra costs of identi-
fying and engaging with high-risk populations were not
taken into consideration. The authors note that the
geographic coverage of identified studies was limited and
that the findings are very dependent on the setting which
limits generalizability.
What Do these Findings Mean? These findings suggest
that PrEP could be a cost-effective tool to reduce new HIV
infections in some settings. However, the cost-effectiveness
of PrEP is dependent upon cost, the epidemic context,
program coverage and prioritization strategies, participants’
adherence to the drug regimen, and PrEP efficacy estimates.
These findings will aid decision makers quantify and
compare the reductions in HIV incidence that could be
achieved by implementing a PrEP program.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001401.
N The US National Institute of Allergy and Infectious Diseases
has information on HIV/AIDS
N aidsmap provides basic information about HIV/AIDS,
summaries of recent research findings on HIV care and
treatment, and has a section on PrEP
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including HIV
prevention
N AVAC Global Advocacy for HIV Prevention provides infor-
N The US Centers for Disease Control and Prevention also has
information on PrEP
N The World Health Organization has a page on its WHO-
CHOICE criteria for cost-effectiveness
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mation on HIV prevention, including PrEP
